Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Alveolar Ridge Preservation Using Autogenous Tooth Graft Versus Autogenous Demineralized Dentin Graft. (ARP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03447795
Recruitment Status : Completed
First Posted : February 27, 2018
Last Update Posted : November 10, 2020
Sponsor:
Information provided by (Responsible Party):
Ahmed Mohamed AbdelRaouf Hussein, Cairo University

Brief Summary:
Alveolar bone resorption following tooth extraction is unavoidable. Graft placement following extraction is recommended when considering restorative procedures afterwards. The extracted tooth was considered a clinical waste. However, it is now seen as a convenient and available source for graft material. Different protocols are applied to process the extracted tooth for obtaining the graft material and investigations are needed to assess the protocol with the best outcome.

Condition or disease Intervention/treatment Phase
Alveolar Ridge Preservation Dentin Graft Autogenous Tooth Bone Graft Procedure: Alveolar ridge preservation Not Applicable

Detailed Description:

Autogenous graft is widely accepted as the gold standard for grafting procedures(Sakkas et al. 2017). And since the introduction of autogenous dentin graft for alveolar ridge preservation by Kim et al. clinically (Y.-K. Kim et al. 2010), it has increasingly attracted attention and teeth are no longer seen only as a waste. Tooth dentin has a chemical composition similar to that of alveolar bone; the inorganic content is 70%-75%, organic content 20%, and water content 10%, whereas alveolar bone has proportions of 65%, 25%, and 10% respectively(Y.-K. Kim et al. 2013). The similarity in chemical composition between dentin and alveolar bone, as well as its content of growth factors such as bone morphogenetic proteins (BMPs), made the dentin a successful graft for filing alveolar bone defects of same patient(Y.-K. Kim et al. 2010, Nampo et al. 2010, Y.-K. Kim et al. 2013) .

The technique proposed by Kim et al includes demineralization of the dentin as it reduces minerals content, exposes collagen fibrils and increases BMPs released thus promoting the process of osteogenesis(Y.-K. Kim et al. 2010). However, demineralisation step is time-consuming, taking several days, which challenges same visit application. As a result, two main approaches have been developed to overcome this obstacle. One approach is to maintain the demineralization step but with improving the technique to shorten the processing time(MURATA et al. 2010, E.-S. Kim 2015, Kabir et al. 2015). On the other hand, many investigators have used the whole tooth without demineralization and reported satisfactory clinical outcome(Gideon Hallel et al. 2014, Valdec et al. 2017). Hence, more investigations are needed to evaluate the technique with the best outcome.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized controlled clinical trial (RCT) with parallel group, two arm, with 1:1 allocation ratio.
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Alveolar Ridge Preservation Using Autogenous Tooth Graft Versus Autogenous Demineralized Dentin Graft. A Randomized Controlled Clinical Trial.
Actual Study Start Date : February 1, 2019
Actual Primary Completion Date : March 1, 2020
Actual Study Completion Date : June 1, 2020

Arm Intervention/treatment
Experimental: autogenous tooth grafted sites Procedure: Alveolar ridge preservation
grafting procedure using autogenous tooth.
Other Name: ARP

Active Comparator: autogenous demineralised dentin grafted sites Procedure: Alveolar ridge preservation
grafting procedure using autogenous tooth.
Other Name: ARP




Primary Outcome Measures :
  1. Cone beam computed tomography (CBCT) analysis [ Time Frame: immediately and after 6 months of grafting ]
    CBCT scans will be taken at first day and at 6 months after the grafting procedures. The scans will be compared using predetermined reference points, buccolingual and vertical dimensions will be measured in cross-sectional images using the same reference points and lines. The difference in mm will be subtracted.


Secondary Outcome Measures :
  1. Histological analysis [ Time Frame: after 6 months of grafting ]
    Bone samples from at least one control and one intervention site will be taken during implant placement. Patients will be asked to sign and additional informed consent. A trephine bur will be used to obtain samples and then sent to the department of oral histology for assessment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients with non-restorable non-molar teeth
  • Patients > 18 years old
  • Motivated patients who are willing to continue the follow-up period

Exclusion Criteria:

  • Compromised alveolar socket that is not contained to support graft material
  • smokers and alcoholic patients.
  • Patients with systemic conditions that may compromise hard tissue healing (i.e. poorly controlled diabetes, autoimmune diseases).
  • Local infection at the site of extraction.
  • Teeth with root canal filling.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03447795


Locations
Layout table for location information
Egypt
Cairo University
Cairo, Egypt
Sponsors and Collaborators
Cairo University
Layout table for additonal information
Responsible Party: Ahmed Mohamed AbdelRaouf Hussein, Dr. Ahmed Elfana, Cairo University
ClinicalTrials.gov Identifier: NCT03447795    
Other Study ID Numbers: 19|01|02
First Posted: February 27, 2018    Key Record Dates
Last Update Posted: November 10, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No